The 10th annual Babraham Investor Conference is taking place in Cambridge on 15 May 2019
As well as expert-led panel discussions and sessions focused on scale-up and venture-stage growth companies, investors will hear pitches from a broad spectrum of early stage and scale-up companies seeking investment.
Taking place at the Babraham Research Campus, the conference will also include company presentations, talks from guest speakers on sector specific issues and invaluable networking opportunities.
“There have been many success stories from the last 10 years of Babraham Investor Conferences,” said the Babraham Research Campus CEO Derek Jones. “Not only have investors discovered original opportunities and entrepreneurial ideas to invest in, they have also developed new relationships with other investors and innovators. As a Campus our objective is to support jobs and growth in the bio-sciences sector, and we are particularly focused on those ventures which are in the very early stages or scaling up. We are lucky to be part of an active and integrated biotech community and as such our role in organising events, like BIC, to bring together the full spectrum of stakeholders involved in taking conceptual research through to commercially viable business propositions, is a critical and valuable part of that ecosystem. The result of which not only positively impacts the Cambridge cluster, but UK bioscience as a whole.”
BIC 2019 is sponsored by Taylor Vinters and Handelsbanken.
Patrick Farrant, Partner, Taylor Vinters said: “We are excited to again be a part of BIC which supports the growth of early-stage and scale-up life science and med-tech companies – which is a core focus for Taylor Vinters. BIC offers an invaluable platform to allow these innovative companies to grow and develop relationships with like-minded investors – and takes place at the fabulous conference facilities on the Babraham Research Campus.”
Paul Smith, Cambridge MR Branch Manager, Handelsbanken said: “We are delighted to be involved with BIC once again this year. Supporting and nurturing early-stage biotech ventures and enabling them to develop potentially long-term relationships with experienced and prolific investors in the life-science arena speaks directly to our wider corporate banking ethos – bespoke solutions and long-term relationships that combine to have a real impact on business success. As in previous years, we look forward to being part of an energetic and innovative event, which yields tangible results for the ventures involved.”